08 July 2010 - Biotica consolidates leadership in polyketide therapeutics and extends platform
Biotica has acquired polyketide engineering IP originating from Stanford and Harvard Universities and from Kosan Pharmaceuticals.
06 April 2010 - Biotica achieves preclinical proof-of-concept in its nPT-CyP hepatitis C programme
Biotica's cyclophilin inhibitor programme for the treatment of hepatitis C virus, has reached preclinical proof of concept.
28 October 2009 - Dr. Edward Hodgkin elected to the Board of Directors of BIA
Biotica CEO, Dr. Edward Hodgkin, has been elected to the Board of Directors of the BioIndustry Association (BIA).
02 October 2009 - Biotica achieves preclinical proof-of-concept in nPT-CLN asthma programme
nPT-CLN compounds for inhaled use in asthma show high local potency against calcineurin, but minimal systemic exposure when given by inhalation, orally or IV.
11 September 2009 - Biotica alliance with GSK shortlisted for prestigious Scrip Award
The alliance, announced in January 2009, covers Biotica's nPT-ery programme of novel erythromycin analogues for use in anti-inflammatory indications
Biotica has acquired polyketide engineering IP originating from Stanford and Harvard Universities and from Kosan Pharmaceuticals.
06 April 2010 - Biotica achieves preclinical proof-of-concept in its nPT-CyP hepatitis C programme
Biotica's cyclophilin inhibitor programme for the treatment of hepatitis C virus, has reached preclinical proof of concept.
28 October 2009 - Dr. Edward Hodgkin elected to the Board of Directors of BIA
Biotica CEO, Dr. Edward Hodgkin, has been elected to the Board of Directors of the BioIndustry Association (BIA).
02 October 2009 - Biotica achieves preclinical proof-of-concept in nPT-CLN asthma programme
nPT-CLN compounds for inhaled use in asthma show high local potency against calcineurin, but minimal systemic exposure when given by inhalation, orally or IV.
11 September 2009 - Biotica alliance with GSK shortlisted for prestigious Scrip Award
The alliance, announced in January 2009, covers Biotica's nPT-ery programme of novel erythromycin analogues for use in anti-inflammatory indications